



Prior Authorization – Risperdal Consta® 12.5mg, 25mg, 37.5mg, and 50mg for Title XIX and Title XXI Members

Maricopa County/ Magellan

Updated: 4/22/2011

Guidelines for approval:

1. Recipient has a diagnosis of Bipolar I disorder or a schizophrenic-spectrum disorder.
2. The behavioral health recipient is not receiving concomitant treatment with carbamazepine. Carbamazepine induces the metabolism of risperidone and can significantly decrease the plasma levels of Risperdal Consta®.
3. Requests for dose increases above 25mg every 2 weeks will be considered for partial responders after the administration of 4 consecutive injections (total of 8 weeks). For non-responders, requests will be considered after the administration of the second consecutive injection (total of 4 weeks). Increases for Risperdal Consta 12.5 mg injections will be considered after the first injection.
4. Initial authorization will be for 120 days.
5. Improvement of target symptoms must be documented and submitted as part of the clinical information.
6. New behavioral health recipients that are stable on a higher dose of Risperdal Consta® and meet all other criteria will not be required to try a lower dose prior to approval.

References:

1. Risperdal Consta® package insert. Ltd. Revised 1/2011. Janssen Pharmaceutical. Accessed 4/11/2011: <http://www.janssencns.com/sites/default/files/pdf/risperdal/risperdalconsta.pdf>